• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Detailed Time Course of Decline in Serum C-Peptide Levels in Anti-Programmed Cell Death-1 Therapy-Induced Fulminant Type 1 Diabetes.

作者信息

Saito Daigo, Oikawa Yoichi, Yano Yuya, Ikegami Yuichi, Satomura Atsushi, Isshiki Masashi, Kurihara Susumu, Inoue Ikuo, Noda Mitsuhiko, Shimada Akira

机构信息

Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan.

Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan

出版信息

Diabetes Care. 2019 Mar;42(3):e40-e41. doi: 10.2337/dc18-1673. Epub 2019 Jan 18.

DOI:10.2337/dc18-1673
PMID:30659072
Abstract
摘要

相似文献

1
Detailed Time Course of Decline in Serum C-Peptide Levels in Anti-Programmed Cell Death-1 Therapy-Induced Fulminant Type 1 Diabetes.抗程序性细胞死亡蛋白1治疗诱导的暴发性1型糖尿病患者血清C肽水平下降的详细时间进程
Diabetes Care. 2019 Mar;42(3):e40-e41. doi: 10.2337/dc18-1673. Epub 2019 Jan 18.
2
Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in 'anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes.在“抗程序性细胞死亡蛋白 1 抗体诱导”暴发性 1 型糖尿病中，停止抗程序性细胞死亡蛋白 1 抗体治疗可能会保留内在胰岛素分泌能力。
J Diabetes Investig. 2018 Mar;9(2):448-449. doi: 10.1111/jdi.12662.
3
Pancreatic exocrine and endocrine events occur concomitantly but independently during the course of fulminant type 1 diabetes.在暴发性1型糖尿病病程中，胰腺外分泌和内分泌事件同时发生但相互独立。
Diabetes Res Clin Pract. 2006 Mar;71(3):241-6. doi: 10.1016/j.diabres.2005.07.003. Epub 2005 Aug 19.
4
Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.接受免疫检查点抑制剂纳武单抗治疗的患者发生无痛性甲状腺炎和暴发性1型糖尿病
Tohoku J Exp Med. 2018 Jan;244(1):33-40. doi: 10.1620/tjem.244.33.
5
Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes.抗程序性细胞死亡1疗法引发糖尿病酮症酸中毒和暴发性1型糖尿病。
Acta Diabetol. 2016 Oct;53(5):853-6. doi: 10.1007/s00592-016-0872-y. Epub 2016 Jun 14.
6
Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.一名复发经典型霍奇金淋巴瘤患者中与纳武单抗相关的暴发性1型糖尿病。
Int J Hematol. 2017 Mar;105(3):383-386. doi: 10.1007/s12185-016-2101-4. Epub 2016 Oct 1.
7
Low gene expression levels of activating receptors of natural killer cells (NKG2E and CD94) in patients with fulminant type 1 diabetes.自然杀伤细胞（NKG2E 和 CD94）激活受体在暴发性 1 型糖尿病患者中的低基因表达水平。
Immunol Lett. 2013 Nov-Dec;156(1-2):149-55. doi: 10.1016/j.imlet.2013.10.004. Epub 2013 Oct 25.
8
Immunological aspects of 'fulminant type 1 diabetes'.“暴发性1型糖尿病”的免疫学方面
Diabetes Res Clin Pract. 2007 Sep;77 Suppl 1:S99-103. doi: 10.1016/j.diabres.2007.01.041. Epub 2007 May 2.
9
Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy--a nationwide 5-year-study in Japan.暴发性1型糖尿病作为糖尿病微血管病变的高危人群——日本一项全国性5年研究
Diabetologia. 2007 Mar;50(3):531-7. doi: 10.1007/s00125-006-0575-y. Epub 2007 Jan 18.
10
Incidence and development of diabetic microangiopathy of fulminant type 1 diabetes--comparison with non-fulminant type 1 diabetes.暴发性1型糖尿病微血管病变的发病率及发展——与非暴发性1型糖尿病的比较
Intern Med. 2010;49(12):1079-83. doi: 10.2169/internalmedicine.49.3294. Epub 2010 Jun 15.

引用本文的文献

1
Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.免疫检查点抑制剂相关糖尿病的临床和 HLA 基因型分析：来自中国的单中心病例系列。
Front Immunol. 2023 Jun 9;14:1164120. doi: 10.3389/fimmu.2023.1164120. eCollection 2023.
2
Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.PD-1 相关暴发性 1 型糖尿病的临床和免疫学特征。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Jan 28;48(1):49-58. doi: 10.11817/j.issn.1672-7347.2023.220290.
3
Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin.
免疫检查点抑制剂相关暴发性 1 型糖尿病的特征与自身抗体状态和种族起源有关。
Front Immunol. 2022 Nov 14;13:968798. doi: 10.3389/fimmu.2022.968798. eCollection 2022.
4
PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review.程序性死亡蛋白1抑制剂相关的1型糖尿病：1例病例报告及系统评价
Front Public Health. 2022 Aug 5;10:885001. doi: 10.3389/fpubh.2022.885001. eCollection 2022.
5
Fulminant type 1 diabetes: recent research progress and future prospects.暴发性1型糖尿病：最新研究进展与未来展望
Diabetol Int. 2020 Sep 16;11(4):336-341. doi: 10.1007/s13340-020-00466-2. eCollection 2020 Oct.
6
Possible involvement of autoimmunity in fulminant type 1 diabetes.自身免疫在暴发性1型糖尿病中的可能作用。
Diabetol Int. 2020 Aug 27;11(4):329-335. doi: 10.1007/s13340-020-00460-8. eCollection 2020 Oct.
7
Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.派姆单抗诱发暴发性1型糖尿病，初诊时C肽持续存在。
Endocrinol Diabetes Metab Case Rep. 2020 Apr 29;2020. doi: 10.1530/EDM-19-0152.
8
Serum 1,5-Anhydroglucitol to Glycated Albumin Ratio Can Help Early Distinguish Fulminant Type 1 Diabetes Mellitus from Newly Onset Type 1A Diabetes Mellitus.血清 1,5-脱水葡萄糖醇与糖化白蛋白比值有助于早期鉴别暴发性 1 型糖尿病与新发 1A 型糖尿病。
J Diabetes Res. 2020 Mar 20;2020:1243630. doi: 10.1155/2020/1243630. eCollection 2020.
9
Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.纳武利尤单抗致暴发性 1 型糖尿病伴 C 肽水平急剧下降
J Diabetes Investig. 2020 May;11(3):748-749. doi: 10.1111/jdi.13143. Epub 2019 Oct 6.
10
A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.一名患有与纳武单抗相关的暴发性1型糖尿病的患者，其血清C肽水平在高血糖初次检测时保持正常。
Intern Med. 2019 Oct 1;58(19):2825-2830. doi: 10.2169/internalmedicine.2780-19. Epub 2019 Jun 27.